ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) enjoyed a 11.52% run-up in share price since hitting record low of $4.03. The stock managed 6.89% rise and now stands at $4.5 as of 11/15/2017. At recent session, the prices were hovering between $4.09 and $4.62. This company shares are 177.78% off its target price of $12.5 and the current market capitalization stands at $675.95M. The recent change has given its price a -19.39% deficit over SMA 50 and -42.89% deficit over its 52-week high. The stock witnessed -21.19% declines, -12.62% declines and -38.86% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ZIOP’s volatility during a week at 10.74% and during a month it has been found around 7.13%.ZIOPHARM Oncology, Inc. (ZIOP) Top Holders
Institutional investors currently hold around $244 million or 51.2% in ZIOP stock. Look at its top three institutional owners. Third Security, Llc owns $40.88 million in ZIOPHARM Oncology, Inc., which represents roughly 6.05% of the company’s market cap and approximately 16.75% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 8,219,206 shares of the stock are valued at $34.6 million. The third largest holder is Vanguard Group Inc, which currently holds $34.47 million worth of this stock and that ownership represents nearly 5.1% of its market capitalization.
At the end of 09/30/2017 reporting period, 43 institutional holders increased their position in ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) by some 1,705,797 shares, 51 decreased positions by 4,635,590 and 41 held positions by 51,578,257. That puts total institutional holdings at 57,919,644 shares, according to SEC filings. The stock grabbed 8 new institutional investments totaling 152,460 shares while 14 institutional investors sold out their entire positions totaling 449,675 shares.ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Insider Trades
Multiple company employees have indulged in significant insider trading. ZIOPHARM Oncology, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that EVP and Chief Business Officer Mauney David M Md has acquired 4,270 shares of ZIOPHARM Oncology, Inc. (ZIOP) in trading session dated Nov. 08, 2017. These shares are worth $19,984 and were traded at $4.68 each. The SEC filing shows that Cooper Laurence James Neil performed a purchase of 6,440 shares. The CEO added these shares by way of transaction on Nov. 08, 2017. The company’s shares were assimilated at $4.68 per share worth to an investment of some $30,139 on account of Cooper Laurence James Neil.
COO, CLO, and Secretary, Belbel Caesar J, sold 153,333 common shares of ZIOPHARM Oncology, Inc. (ZIOP) in the open market. In a transaction dated Nov. 19, 2015, the shares were put up for sale at an average price of $12.84, raking in a sum of $1,968,796. After this sale, 59,201 common shares of ZIOP are directly owned by the insider, with total stake valued at $266,405.
In the transaction dated Jun. 09, 2015, the great number of shares disposed came courtesy the Executive Vice President R&D; Lebel Francois disposed a total of 50,000 shares at an average price of $10.12, amounting to approximately $506,000.ZIOPHARM Oncology, Inc. (ZIOP) Analyst Guide
Several analysts have released their opinion on ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), with 2 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.2 average brokerage recommendation.